Repligen (NASDAQ:RGEN) Upgraded to "Outperform" at Wolfe Research

Repligen (NASDAQ:RGEN - Get Free Report) was upgraded by stock analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating in a research report issued on Tuesday, Marketbeat.com reports. The firm currently has a $160.00 price objective on the biotechnology company's stock. Wolfe Research's price target indicates a potential upside of 12.08% from the company's previous close.

RGEN has been the topic of a number of other research reports. JPMorgan Chase & Co. upped their target price on shares of Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a report on Friday, February 21st. Evercore ISI initiated coverage on Repligen in a research report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price target for the company. Canaccord Genuity Group reduced their target price on shares of Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research note on Wednesday, April 16th. Royal Bank of Canada lifted their target price on shares of Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a research report on Friday, February 21st. Finally, HC Wainwright restated a "buy" rating and set a $180.00 price objective on shares of Repligen in a report on Friday, February 21st. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $175.42.

Repligen Trading Down 0.6 %

Shares of Repligen stock traded down $0.87 on Tuesday, hitting $142.76. 1,451,034 shares of the company's stock traded hands, compared to its average volume of 715,860. Repligen has a one year low of $102.97 and a one year high of $182.52. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The company has a fifty day moving average of $139.66 and a two-hundred day moving average of $145.97. The company has a market capitalization of $8.02 billion, a price-to-earnings ratio of -282.28, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27.

Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.35 by $0.04. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. During the same quarter in the prior year, the firm posted $0.28 EPS. The firm's quarterly revenue was up 10.4% compared to the same quarter last year. As a group, sell-side analysts expect that Repligen will post 1.72 earnings per share for the current year.

Insider Buying and Selling at Repligen

In related news, Director Margaret Pax bought 250 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the purchase, the director now directly owns 1,043 shares of the company's stock, valued at $157,169.67. This trade represents a 31.53 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 1.20% of the company's stock.

Hedge Funds Weigh In On Repligen

A number of institutional investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD grew its position in Repligen by 11.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock valued at $1,027,165,000 after acquiring an additional 743,815 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Repligen by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company's stock worth $734,251,000 after acquiring an additional 56,723 shares in the last quarter. Champlain Investment Partners LLC lifted its stake in shares of Repligen by 8.6% in the 4th quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company's stock valued at $222,176,000 after purchasing an additional 122,595 shares during the period. Alliancebernstein L.P. boosted its position in shares of Repligen by 23.4% during the fourth quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company's stock valued at $145,508,000 after purchasing an additional 191,439 shares in the last quarter. Finally, Conestoga Capital Advisors LLC grew its stake in Repligen by 3.4% in the first quarter. Conestoga Capital Advisors LLC now owns 980,247 shares of the biotechnology company's stock worth $124,727,000 after purchasing an additional 32,665 shares during the period. Institutional investors own 97.64% of the company's stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.